New International IgG4-RD Guidelines and the Road Ahead

In "New International IgG4-RD Guidelines and the Road Ahead," the panel considers how new recommendations may standardize care worldwide.

Dr. Culver asks which recommendations in the new international guidelines are most novel or practice changing. Dr. Katz says the most important development is that well-designed guidelines now exist. They were developed by a large international group spanning many countries and specialties. Clinicians, pathologists, radiologists, and patients all took part. He considers consensus across such a varied group to be their most valuable feature.

He sees several practice-changing elements, especially for clinicians with less experience in the disease. Among his favorites are recommendations on glucocorticoids. The guidelines explicitly limit both the maximum dose and the duration to a few months, which is enough for most patients. They also emphasize using B-cell-targeted therapies up front in many patients.

Dr. Della Torre adds that these are the first guidelines to incorporate evidence from randomized clinical trials. They encourage a consistent worldwide approach regardless of the organ involved. That approach covers both currently available treatments and agents expected to become available. Earlier guidelines, which the group also developed, lacked this evidence. He views the new guidelines as a hallmark and a starting point for homogenizing care.

Dr. Culver welcomes the new emphasis on managing complications of the disease. Earlier guidelines focused largely on active disease, glucocorticoids, conventional disease-modifying drugs, and B-cell therapies. The new guidelines also address multispecialty care for complications and attention to patients' quality of life.

Finally, Dr. Culver asks what will make the greatest difference for patients going forward. Dr. Della Torre points to the expanding range of treatment options now available and expected over the next few years. He tells patients that research is moving fast. Treatment for someone diagnosed in 2026 will likely differ in 2, 3, or 4 years. He says the discussion leaves him trusting the future and hopeful for more individualized care.

Thank you for watching this HCPLive Peer Exchange series on IgG4-related disease. Please subscribe to our eNewsletter for information on upcoming video series.